Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma.
Eager RM, Cunningham CC, Senzer NN, Stephenson J Jr, Anthony SP, O'Day SJ, Frenette G, Pavlick AC, Jones B, Uprichard M, Nemunaitis J. Eager RM, et al. Among authors: senzer nn. BMC Cancer. 2009 Jul 30;9:263. doi: 10.1186/1471-2407-9-263. BMC Cancer. 2009. PMID: 19643020 Free PMC article. Clinical Trial.
Virus-mediated killing of cells that lack p53 activity.
Nemunaitis J, Senzer N, Cunningham C, Dubensky TW. Nemunaitis J, et al. Drug Resist Updat. 2001 Oct;4(5):289-91. doi: 10.1054/drup.2001.0220. Drug Resist Updat. 2001. PMID: 11991681 Review. No abstract available.
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.
Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, Hanna N. Senzer N, et al. J Clin Oncol. 2004 Feb 15;22(4):592-601. doi: 10.1200/JCO.2004.01.227. Epub 2004 Jan 15. J Clin Oncol. 2004. PMID: 14726502 Clinical Trial.
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.
Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Wart Hood J, Merritt J, Chada S. Tong AW, et al. Mol Ther. 2005 Jan;11(1):160-72. doi: 10.1016/j.ymthe.2004.09.021. Mol Ther. 2005. PMID: 15585417 Free article. Clinical Trial.
119 results